We can’t show the full text here under this license.
A two-part self-boosting system for vaccines and nanomedicines without lipid nanoparticles
Updated
Abstract
Essence
The Gemini /DNA platform is presented as an LNP-free route for more stable genetic vaccines and nanomedicines.
Evidence
This platform experiment reports a bifunctional promoter system usable as saRNA or , with freeze-thaw, lyophilization, ambient-storage, payload, expression, safety-profile, manufacturing, and single-dose SARS-CoV-2 vaccine demonstrations.
Caveat
The abstract does not specify human clinical testing, so claims about broad medical and pandemic use remain platform-level rather than proven clinical outcomes.
Simplified
Key numbers
98%
Increase in expression (-)
Percentage of cells positive for at day 14 post-injection.
6×
6-fold reduction in expression ()
Reduction in expression from by day 6 compared to day 2.
~3.4 × 10
Integration frequency of
Estimated copies of integrated per cell genome.
mRNA Technology